A Phase IV, Double-Blind, Placebo-Controlled, Multi-Center Trial To Study The Effects Of Evolocumab In Stage IV-V Chronic Kidney Disease: The Cardiovascular and Lipid-Lowering Effects Of Evolocumab In Advanced Chronic Kidney Disease Trial
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms EVO-CKD
- 27 Jul 2022 Status changed from discontinued to withdrawn prior to enrolment.
- 12 May 2022 Status changed from recruiting to discontinued.
- 27 May 2021 Status changed from not yet recruiting to recruiting.